Biomind Labs Advances New Obesity Treatment with BMND06 Candidate Targeting Neurological Pathways

Biomind Labs Inc. (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI) announced the advancement to a Phase II clinical trial for its BMND06 compound. New findings from pre-clinical studies revealed that BMND06 is physiologically safe, with low toxicity and no mutagenic effects. The candidate also demonstrated significant anti-inflammatory properties, outperforming the corticosteroid dexamethasone in reducing IL-6 levels in colon cancer cell lines.

The CEO, Alejandro Antalich, highlighted the growing obesity problem, noting that traditional obesity treatments are inadequate. He emphasized that BMND06 has shown potency as an anti-inflammatory, without the side effects of corticosteroids, suggesting its potential in treating obesity by targeting neurological pathways. This approach could redefine obesity treatment, addressing neuroinflammation linked to the condition.

Beyond obesity, elevated IL-6 levels, which BMND06 significantly reduces, are associated with a range of health issues including cardiovascular diseases, metabolic syndrome, and non-cardiovascular diseases such as cancer.

The positive preclinical evidence supports the launch of a Phase II clinical trial focusing on obesity, without the necessity for further preclinical assays, marking a significant step in Biomind's commitment to developing novel pharmaceutical treatments for neurological conditions.